$115.07
+0.00 (+0.00%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+0.00%
1Y
+30.46%
YTD
+81.67%
Open$115.07
Previous Close$115.07
Day High$115.07
Day Low$115.07
52W High$115.13
52W Low$60.36
Volume—
Avg Volume2.16M
Market Cap6.73B
P/E Ratio—
EPS$-4.06
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$112.63
Above
SMA 200
$84.18
Above
RSI (14)
73.1
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Hold
14 analysts
Price Target
-15.7% upside
Current
$115.07
$115.07
Target
$96.95
$96.95
$73.10
$96.95 avg
$131.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 23.15M | 2.26B | 2.06B |
| Net Income | -237,773,068 | 113.46M | 99.51M |
| Profit Margin | -1,027.3% | 5.0% | 4.8% |
| EBITDA | -255,919,354 | 251.62M | 213.71M |
| Free Cash Flow | — | 62.68M | 52.56M |
| Rev Growth | — | +18.8% | +20.4% |
| Debt/Equity | — | 0.80 | 0.97 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |